Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Burn patients needed for antibiotic dosing study

NCT ID NCT07465432

First seen Mar 20, 2026 · Last updated Jun 16, 2026 · Updated 19 times

Summary

This study looks at how the antibiotic cefiderocol behaves in the bodies of people with severe burns. Researchers want to find the best dose to kill bacteria and prevent resistance. The study will enroll 12 adults with burns who have good kidney function.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRUG CLEARANCE AFTER SEVERE BURN INJURY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Regional One Health

    RECRUITING

    Memphis, Tennessee, 38103, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

burn gram-negative bacterial infections

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.